GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley Sells 3,749 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 3,749 shares of the business’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $96.71, for a total transaction of $362,565.79. Following the completion of the sale, the chief financial officer now owns 8,492 shares of the company’s stock, valued at $821,261.32. The trade was a 30.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Kevin Feeley also recently made the following trade(s):

• On Thursday, March 13th, Kevin Feeley sold 402 shares of GeneDx stock. The stock was sold at an average price of $90.05, for a total transaction of $36,200.10.
• On Monday, March 10th, Kevin Feeley sold 922 shares of GeneDx stock. The stock was sold at an average price of $94.72, for a total transaction of $87,331.84.
• On Wednesday, January 29th, Kevin Feeley sold 275 shares of GeneDx stock. The shares were sold at an average price of $78.48, for a total transaction of $21,582.00.
• On Tuesday, January 7th, Kevin Feeley sold 35,506 shares of GeneDx stock. The shares were sold at an average price of $93.82, for a total transaction of $3,331,172.92.
• On Thursday, January 2nd, Kevin Feeley sold 1,430 shares of GeneDx stock. The shares were sold at an average price of $76.04, for a total transaction of $108,737.20.

GeneDx Stock Performance

GeneDx stock opened at $94.46 on Tuesday. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. GeneDx Holdings Corp. has a 1 year low of $7.72 and a 1 year high of $115.60. The company has a market cap of $2.65 billion, a PE ratio of -48.19 and a beta of 1.91. The company’s 50-day moving average is $84.69 and its two-hundred day moving average is $70.37.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings results on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.66. The company had revenue of $95.64 million during the quarter, compared to analysts’ expectations of $82.24 million. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. Equities analysts anticipate that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

Institutional Trading of GeneDx

A number of large investors have recently bought and sold shares of WGS. MCF Advisors LLC increased its stake in GeneDx by 107.7% during the 4th quarter. MCF Advisors LLC now owns 351 shares of the company’s stock worth $27,000 after purchasing an additional 182 shares in the last quarter. Sterling Capital Management LLC boosted its holdings in shares of GeneDx by 877.8% in the 4th quarter. Sterling Capital Management LLC now owns 352 shares of the company’s stock valued at $27,000 after buying an additional 316 shares during the last quarter. Global Retirement Partners LLC acquired a new stake in shares of GeneDx in the 4th quarter valued at approximately $28,000. Lazard Asset Management LLC acquired a new stake in GeneDx during the 4th quarter valued at $35,000. Finally, Comerica Bank acquired a new stake in GeneDx during the 4th quarter valued at $50,000. 61.72% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

WGS has been the topic of several recent analyst reports. TD Cowen boosted their target price on shares of GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a research note on Tuesday, January 7th. The Goldman Sachs Group upped their price target on shares of GeneDx from $70.00 to $80.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 19th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, GeneDx currently has a consensus rating of “Moderate Buy” and a consensus target price of $72.33.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.